The global viral vector and plasmid DNA manufacturing sector is entering a period of rapid expansion as gene therapy, cell therapy, vaccine development, and advanced biotechnology continue to progress. The sector was valued at approximately USD 8.77 billion in 2025 and is projected to reach USD 57.55 billion by 2035, expanding at a 20.7% CAGR from 2026 to 2035. In 2026, the sector is expected to reach around USD 10.59 billion.
Viral vectors and plasmid DNA play an important role in genetic research and therapeutic development. Plasmids are widely used to carry and modify genetic material, while viral vectors help deliver genetic information into specific cells. Their growing use in gene therapies, cancer treatments, vaccines, and rare disease research is creating strong demand for reliable and scalable manufacturing capabilities.
Key Trends Driving Growth
The increasing prevalence of genetic disorders is one of the major factors supporting growth. Researchers and biotechnology companies are investing heavily in gene and cell therapies that can address diseases at the genetic level. Personalized medicine is also creating new opportunities as treatment approaches increasingly focus on individual patient needs.
Artificial intelligence is emerging as another important development. AI and machine learning can analyze large volumes of genetic data, identify patterns in DNA sequences, and support the design of complex vectors containing multiple genes or regulatory elements. This could help improve development speed, precision, and manufacturing efficiency.
Sustainability is also gaining attention. Manufacturers are exploring ways to reduce water consumption, minimize waste, remove impurities more efficiently, and develop scalable production techniques with lower environmental impact.
Regional and Segment Highlights
North America held the leading position, accounting for 49.20% in 2025, supported by advanced biotechnology infrastructure, strong research capabilities, government funding, and significant investment in gene and cell therapy.
Asia Pacific is expected to record the fastest growth. The region’s large patient population, expanding biotechnology sector, vaccine development activities, and improving regulatory environment are encouraging further investment.
By vector type, adeno-associated virus (AAV) remained the leading segment in 2025. Cancer represented the largest disease segment, while downstream processing held the leading position within workflow. Vaccinology was the dominant application, and research institutes accounted for the largest end-use share.
Download a Sample Report: https://www.towardshealthcare.com/download-sample/5199
Looking Ahead
New manufacturing facilities, CDMO investments, technological improvements, and increasing research activity are expected to strengthen the sector over the coming years. Developments from companies such as ProBio, Asahi Kasei, Lonza, Merck, and FUJIFILM Diosynth Biotechnologies further demonstrate the growing focus on expanding viral vector and plasmid DNA production capabilities.
With continued innovation in gene-based treatments and biotechnology, viral vector and plasmid DNA manufacturing is positioned to become an increasingly important foundation for next-generation therapies.
About Us
Healthcare WebWire is a part of Towards Healthcare Research & Consulting which is a global healthcare market research and consulting firm dedicated to helping businesses make informed decisions through reliable market intelligence and strategic insights. We serve pharmaceutical, biotechnology, medical device, AI in healthcare, cell and gene therapy, digital health, and life sciences organizations with in-depth market research, custom consulting, competitive analysis, and growth forecasts. Our team combines industry expertise with rigorous research to deliver clear, actionable insights that support market expansion, product strategy, investment decisions, and long-term business growth. From emerging innovations to established healthcare markets, we help organizations understand where the industry is today and where it’s headed tomorrow.
You can place an order or ask any questions, please feel free to contact us at [email protected]
Europe Region – +44 778 256 0738
North America Region – +1 8044 4193 44
APAC Region: +91 9356 9282 04
Visit Our Website: Towards Healthcare Research & Consulting – Expert Consulting Solutions & Research Reports
Find us on social platforms: LinkedIn | Twitter | Instagram | Medium